Connective Capital Management LLC Takes $787,000 Position in Profound Medical $PROF

Posted by on Jun 19th, 2026

Connective Capital Management LLC purchased a new stake in Profound Medical (NASDAQ:PROF – Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 100,000 shares of the company’s stock, valued at approximately $787,000. Profound Medical comprises 0.5% of Connective Capital Management LLC’s portfolio, making the stock its 23rd largest holding.

Several other hedge funds have also added to or reduced their stakes in the company. Goldman Sachs Group Inc. increased its position in Profound Medical by 56.8% in the fourth quarter. Goldman Sachs Group Inc. now owns 18,727 shares of the company’s stock worth $147,000 after purchasing an additional 6,787 shares during the period. Corsair Capital Management L.P. acquired a new position in Profound Medical during the 4th quarter valued at about $208,000. Millennium Management LLC acquired a new position in Profound Medical during the 4th quarter valued at about $211,000. Quadrature Capital Ltd bought a new position in shares of Profound Medical in the 4th quarter valued at about $256,000. Finally, T3 Companies LLC bought a new position in shares of Profound Medical in the 4th quarter valued at about $378,000. Institutional investors own 47.86% of the company’s stock.

Profound Medical Trading Up 4.6%

Shares of PROF opened at $6.87 on Friday. The stock has a market cap of $249.66 million, a P/E ratio of -5.54 and a beta of 0.72. Profound Medical has a 1 year low of $3.76 and a 1 year high of $8.95. The stock’s 50-day moving average price is $6.77 and its two-hundred day moving average price is $6.91.

Profound Medical (NASDAQ:PROF – Get Free Report) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($0.19) EPS for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.05. Profound Medical had a negative return on equity of 78.88% and a negative net margin of 206.76%.The company had revenue of $5.34 million during the quarter, compared to analysts’ expectations of $4.85 million. As a group, equities analysts forecast that Profound Medical will post -0.88 EPS for the current year.

Analyst Ratings Changes

Separately, Weiss Ratings cut shares of Profound Medical from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, June 11th. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $12.00.

Check Out Our Latest Research Report on Profound Medical

Profound Medical Profile

(Free Report)

Profound Medical Corp is a medical technology company headquartered in Toronto, Canada, that specializes in the development and commercialization of minimally invasive therapeutic solutions using magnetic resonance–guided ultrasound ablation. The company’s proprietary platform delivers focused ultrasound energy to targeted tissue under real-time MR imaging, offering a non-incisional alternative to traditional surgical approaches.

The company’s lead product, the TULSA-PRO system, is designed for the treatment of prostate conditions, including localized prostate cancer and benign prostatic hyperplasia.

Featured Stories

Want to see what other hedge funds are holding PROF? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Profound Medical (NASDAQ:PROF – Free Report).

Institutional Ownership by Quarter for Profound Medical (NASDAQ:PROF)

Receive News & Ratings for Profound Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Profound Medical and related companies with MarketBeat.com's FREE daily email newsletter.